Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Sandy Cove Advisors LLC

Sandy Cove Advisors LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 14.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,615 shares of the biopharmaceutical company’s stock after buying an additional 567 shares during the quarter. Sandy Cove Advisors LLC’s holdings in Bristol-Myers Squibb were worth $250,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Northwest Financial Advisors bought a new position in Bristol-Myers Squibb in the 4th quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $34,000. VisionPoint Advisory Group LLC boosted its position in Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares during the period. Turtle Creek Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth $40,000. Finally, Wetzel Investment Advisors Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.0 %

Shares of BMY stock traded up $0.02 on Friday, hitting $41.53. 20,542,742 shares of the stock traded hands, compared to its average volume of 15,934,426. The stock has a market capitalization of $84.19 billion, a PE ratio of -13.40, a PEG ratio of 14.21 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm’s 50-day moving average price is $42.97 and its two-hundred day moving average price is $48.14. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the previous year, the firm earned $2.05 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, analysts anticipate that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, BMO Capital Markets reduced their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.